APLS
Price
$17.43
Change
-$0.97 (-5.27%)
Updated
Jun 27 closing price
Capitalization
2.19B
43 days until earnings call
ORMP
Price
$2.15
Change
-$0.02 (-0.92%)
Updated
Jun 27 closing price
Capitalization
87.83M
45 days until earnings call
Interact to see
Advertisement

APLS vs ORMP

Header iconAPLS vs ORMP Comparison
Open Charts APLS vs ORMPBanner chart's image
Apellis Pharmaceuticals
Price$17.43
Change-$0.97 (-5.27%)
Volume$3.83M
Capitalization2.19B
Oramed Pharmaceuticals
Price$2.15
Change-$0.02 (-0.92%)
Volume$59.11K
Capitalization87.83M
APLS vs ORMP Comparison Chart in %
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. ORMP commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and ORMP is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (APLS: $17.43 vs. ORMP: $2.15)
Brand notoriety: APLS and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 151% vs. ORMP: 86%
Market capitalization -- APLS: $2.19B vs. ORMP: $87.83M
APLS [@Biotechnology] is valued at $2.19B. ORMP’s [@Biotechnology] market capitalization is $87.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 3 TA indicator(s) are bullish while ORMP’s TA Score has 0 bullish TA indicator(s).

  • APLS’s TA Score: 3 bullish, 6 bearish.
  • ORMP’s TA Score: 0 bullish, 8 bearish.
According to our system of comparison, APLS is a better buy in the short-term than ORMP.

Price Growth

APLS (@Biotechnology) experienced а -1.47% price change this week, while ORMP (@Biotechnology) price change was +0.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

APLS is expected to report earnings on Aug 11, 2025.

ORMP is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.19B) has a higher market cap than ORMP($87.8M). ORMP YTD gains are higher at: -11.157 vs. APLS (-45.378). ORMP has higher annual earnings (EBITDA): -21.53M vs. APLS (-176.08M). APLS has more cash in the bank: 358M vs. ORMP (131M). ORMP has less debt than APLS: ORMP (301K) vs APLS (470M). APLS has higher revenues than ORMP: APLS (776M) vs ORMP (2M).
APLSORMPAPLS / ORMP
Capitalization2.19B87.8M2,495%
EBITDA-176.08M-21.53M818%
Gain YTD-45.378-11.157407%
P/E RatioN/A20.91-
Revenue776M2M38,800%
Total Cash358M131M273%
Total Debt470M301K156,146%
FUNDAMENTALS RATINGS
APLS vs ORMP: Fundamental Ratings
APLS
ORMP
OUTLOOK RATING
1..100
6116
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
6576
P/E GROWTH RATING
1..100
10051
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (58) in the Pharmaceuticals Other industry is in the same range as APLS (70) in the Medical Distributors industry. This means that ORMP’s stock grew similarly to APLS’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as APLS (100) in the Medical Distributors industry. This means that ORMP’s stock grew similarly to APLS’s over the last 12 months.

ORMP's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as APLS (98) in the Medical Distributors industry. This means that ORMP’s stock grew similarly to APLS’s over the last 12 months.

APLS's Price Growth Rating (65) in the Medical Distributors industry is in the same range as ORMP (76) in the Pharmaceuticals Other industry. This means that APLS’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (51) in the Pharmaceuticals Other industry is somewhat better than the same rating for APLS (100) in the Medical Distributors industry. This means that ORMP’s stock grew somewhat faster than APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSORMP
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
73%
Momentum
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
66%
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 20 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 13 days ago
80%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
85%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TFEQX12.340.11
+0.90%
Templeton Instl Intl Eq Ser Primary
OPGIX49.920.36
+0.73%
Invesco Global Opportunities A
PCEQX24.040.07
+0.29%
Victory Pioneer Equity Income C
DBORX24.440.07
+0.29%
BNY Mellon Balanced Opportunity I
MCVIX31.890.06
+0.19%
MFS Mid Cap Value I

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ROIV. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
-5.27%
ROIV - APLS
46%
Loosely correlated
-1.81%
BPMC - APLS
45%
Loosely correlated
-0.03%
RARE - APLS
44%
Loosely correlated
-2.43%
ARWR - APLS
44%
Loosely correlated
+0.06%
DNLI - APLS
43%
Loosely correlated
-2.69%
More

ORMP and

Correlation & Price change

A.I.dvisor tells us that ORMP and GLSI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ORMP and GLSI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-0.92%
GLSI - ORMP
29%
Poorly correlated
N/A
FULC - ORMP
28%
Poorly correlated
-3.79%
APLS - ORMP
28%
Poorly correlated
-5.27%
PRLD - ORMP
27%
Poorly correlated
-4.64%
SONN - ORMP
27%
Poorly correlated
-2.61%
More